GSMA
8.10.2019 08:02:12 CEST | Business Wire | Press release
Russia will lead the Commonwealth of Independent States (CIS)1 in the commercialisation of 5G services, with the region’s other markets all launching 5G networks by 2025, according to the GSMA’s Mobile Economy: Russia & CIS 2019 report, which was published today at the Mobile 360 Series – Eurasia event in Moscow. The CIS region will have around 54 million 5G connections by 2025, an adoption rate of 13 per cent. Operators are forecast to invest $39 billion in mobile infrastructure between 2019 and 2025, of which over 70 per cent will be 5G-specific.
“5G networks have the potential to transform the digital economy for businesses and citizens alike and our latest report highlights how Russia and the CIS region is preparing to enter this exciting new era,” said Mats Granryd, Director General of the GSMA. “However, in order to capitalise on the tremendous potential of 5G in driving socio-economic growth, regional governments and regulators must adopt policies, such as access to spectrum, that encourage inward investment and encourage the development of the mobile industry.”
4G Networks Growing, Subscriber Adds Slowing
The CIS region had 235 million unique mobile subscribers at the end of 2018, with Russia, Ukraine and Uzbekistan together accounting for 80 per cent. The region has a high unique subscriber penetration rate of 81 per cent, notably in Russia which is approaching saturation point. Future growth will be limited to less than 9 million new unique subscribers in the CIS by 2025. However, the region is also seeing an accelerated shift to mobile broadband driven by greater demand for data-intensive services and higher speeds. 4G is set to become the region’s leading mobile technology in 2021, and will account for over two-thirds of total connections in 2025.
Policies to Support the Digital Economy
The report highlights how delivering 5G connectivity will increase capital intensity for operators, while current uncertainty around spectrum access could be a potential barrier to releasing value into the digital economy. 5G networks have the potential to underpin a range of innovative solutions for businesses and consumers; however, policymakers should also harness the power of 5G to drive growth and the transformation of traditional industries. The regulatory framework should foster the mobile industry’s development within an environment that is conducive to investment. This should be underpinned by a comprehensive national 5G development plan.
Mobile Contributing to the Economy and Employment
The mobile industry contributed $101 billion or 4.7 per cent of GDP to the CIS regional economy in 2018, which is forecast to increase to $122 billion (5.1 per cent of GDP) by 2023. In 2018, the industry contributed 620,000 jobs through direct employment or indirectly through activity in the wider economy. An additional $12 billion was raised in 2018 via general taxation. 5G-related technologies are expected to contribute $34 billion to regional economy over the next 15 years.
Regional Innovation Underpinned by Mobile Connectivity
The report also highlights the potential for operators to expand their businesses beyond traditional communications in areas such as the Internet of Things (IoT), where smart homes and smart buildings will be two key growth verticals out to 2025. The mobile industry is also exploring and implementing applications of artificial intelligence (AI) and blockchain technologies, as well as injecting greater funds into the start-up ecosystem to protect itself from disruption and diversify the revenue mix.
The new report The Mobile Economy Russia & CIS 2019 is authored by GSMA Intelligence . To access the full report and related infographics, please visit: https://www.gsma.com/r/mobileeconomy/russia-cis/
-ENDS-
Notes to Editors
- The Commonwealth of Independent States (CIS) are Armenia, Azerbaijan, Belarus, Georgia, Moldova, Kazakhstan Kyrgyzstan, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005053/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
